Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacqueline Cloos

Showing results (121-130 of 172) with videos related to

Pageof 18
Sort By:
British Journal of Haematology|October 28, 2017
Leukaemic stem cell load at diagnosis predicts the development of relapse in young acute myeloid leukaemia patientsDiana Hanekamp, Barbara Denys, Gertjan J L Kaspers, et al.
Genes, Chromosomes & Cancer|December 20, 2015
miR expression profiling at diagnosis predicts relapse in pediatric precursor B-cell acute lymphoblastic leukemiaSmadar Avigad, Iedan R N Verly, Asaf Lebel, et al.
Blood|July 2, 2010
High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicineCosta Bachas, Gerrit Jan Schuurhuis, Iris H I M Hollink, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2022
Prognostic Value of <i>FLT3</i>-Internal Tandem Duplication Residual Disease in Acute Myeloid LeukemiaTim Grob, Mathijs A Sanders, Christian M Vonk, et al.
Haematologica|August 3, 2019
TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartmentBarbara Depreter, Karin E Weening, Karl Vandepoele, et al.
Blood|June 21, 2008
Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 proteinRuud Oerlemans, Niels E Franke, Yehuda G Assaraf, et al.
Cytometry. Part B, Clinical Cytometry|August 23, 2024
The role of the primitive marker CD133 in CD34-negative acute myeloid leukemia for the detection of leukemia stem cellsTom Reuvekamp, Luca L G Janssen, Lok Lam Ngai, et al.
Oncotarget|August 20, 2016
Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitorsNiels E Franke, Gertjan L Kaspers, Yehuda G Assaraf, et al.
Leukemia|December 10, 2025
Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemiaLukas H Haaksma, Raffaele Palmieri, Tom Reuvekamp, et al.
Haematologica|April 6, 2023
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survivalJesse M Tettero, Lok Lam Ngai, Costa Bachas, et al.
Pageof 18

Showing results (121-130 of 172) with videos related to

Sort By:
Pageof 18
British Journal of Haematology|October 28, 2017
Leukaemic stem cell load at diagnosis predicts the development of relapse in young acute myeloid leukaemia patientsDiana Hanekamp, Barbara Denys, Gertjan J L Kaspers, et al.
Genes, Chromosomes & Cancer|December 20, 2015
miR expression profiling at diagnosis predicts relapse in pediatric precursor B-cell acute lymphoblastic leukemiaSmadar Avigad, Iedan R N Verly, Asaf Lebel, et al.
Blood|July 2, 2010
High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicineCosta Bachas, Gerrit Jan Schuurhuis, Iris H I M Hollink, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2022
Prognostic Value of <i>FLT3</i>-Internal Tandem Duplication Residual Disease in Acute Myeloid LeukemiaTim Grob, Mathijs A Sanders, Christian M Vonk, et al.
Haematologica|August 3, 2019
TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartmentBarbara Depreter, Karin E Weening, Karl Vandepoele, et al.
Blood|June 21, 2008
Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 proteinRuud Oerlemans, Niels E Franke, Yehuda G Assaraf, et al.
Cytometry. Part B, Clinical Cytometry|August 23, 2024
The role of the primitive marker CD133 in CD34-negative acute myeloid leukemia for the detection of leukemia stem cellsTom Reuvekamp, Luca L G Janssen, Lok Lam Ngai, et al.
Oncotarget|August 20, 2016
Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitorsNiels E Franke, Gertjan L Kaspers, Yehuda G Assaraf, et al.
Leukemia|December 10, 2025
Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemiaLukas H Haaksma, Raffaele Palmieri, Tom Reuvekamp, et al.
Haematologica|April 6, 2023
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survivalJesse M Tettero, Lok Lam Ngai, Costa Bachas, et al.
Pageof 18